Apr 30, 2020
Data From EMD Serono at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
Apr 20, 2020
Genome & Company receives FDA IND clearance for GEN-001, its first anti-cancer microbiome therapeutic
Apr 09, 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Mar 13, 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Feb 11, 2020
Phosplatin Therapeutics Presents Positive Data from Two Phase I Studies in Metastatic Castrate-Resistant Prostate Cancer Patients at the 2020 Genitourinary Cancers Symposium
Jan 23, 2020
Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)
Nov 08, 2019
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Oct 28, 2019
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Sep 27, 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Sep 23, 2019
New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care
Sep 20, 2019
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
May 14, 2019
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Sep 11, 2018
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study